154 related articles for article (PubMed ID: 16672130)
1. Therapeutic approach to hormone-refractory prostate cancer.
Saad F; Al Dejmah A; Perrotte P; McCormack M; Bénard F; Valiquette L; Karakiewicz PI
Can J Urol; 2006 Apr; 13 Suppl 2():52-6. PubMed ID: 16672130
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for non-hormone refractory prostate cancer.
Winquist E
Can J Urol; 2006 Feb; 13 Suppl 1():67-70. PubMed ID: 16526986
[TBL] [Abstract][Full Text] [Related]
3. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
4. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
Garmey EG; Sartor O; Halabi S; Vogelzang NJ
Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
[TBL] [Abstract][Full Text] [Related]
5. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
6. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
[TBL] [Abstract][Full Text] [Related]
7. Preservation of bone health in prostate cancer.
Lattouf JB; Saad F
Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
[TBL] [Abstract][Full Text] [Related]
8. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
9. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
Saad F; Perrotte P; Bénard F; McCormack M; Karakiewicz PI
Can J Urol; 2005 Jun; 12 Suppl 2():9-15. PubMed ID: 16018826
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
Semeniuk RC; Venner PM; North S
Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for the treatment of hormone-refractory prostate cancer.
Chowdhury S; Burbridge S; Harper PG
Int J Clin Pract; 2007 Dec; 61(12):2064-70. PubMed ID: 17956560
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F; Karapanagiotou EM; Syrigos KN
Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
[TBL] [Abstract][Full Text] [Related]
13. Role of targeted therapy in the treatment of advanced prostate cancer.
Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
[TBL] [Abstract][Full Text] [Related]
14. Bone health in men receiving androgen deprivation therapy for prostate cancer.
Eastham JA
J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
[TBL] [Abstract][Full Text] [Related]
15. Advances in prostate cancer chemotherapy: a new era begins.
Pienta KJ; Smith DC
CA Cancer J Clin; 2005; 55(5):300-18; quiz 323-5. PubMed ID: 16166075
[TBL] [Abstract][Full Text] [Related]
16. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
17. Advanced prostatic carcinoma. Early versus late endocrine therapy.
Kozlowski JM; Ellis WJ; Grayhack JT
Urol Clin North Am; 1991 Feb; 18(1):15-24. PubMed ID: 1992569
[TBL] [Abstract][Full Text] [Related]
18. Bone metastases in prostate cancer: a targeted approach.
Storey JA; Torti FM
Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
[TBL] [Abstract][Full Text] [Related]
19. The case for early chemotherapy for the treatment of metastatic disease.
Lucas A; Petrylak DP
J Urol; 2006 Dec; 176(6 Pt 2):S72-5. PubMed ID: 17084173
[TBL] [Abstract][Full Text] [Related]
20. Current status of treatment for patients with metastatic prostate cancer.
Higano CS
Can J Urol; 2005 Jun; 12 Suppl 2():38-41. PubMed ID: 16018832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
